Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Apr 6, 2015Adaptimmune Therapeutics PLC is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Oct 28, 2025Removed from listing - SEC Form 25 filed.
SourceADAP stopped trading
Oct 28, 2025ADAP is linked to Adaptimmune Therapeutics PLC and ended with final status "private".
Source
Entity Graph
Adaptimmune Therapeutics PLCissuedADAP
ADAPlisted onNASDAQ
ADAPresulted inunknown
Source-Backed Claims
- On October 15, 2025, Adaptimmune Therapeutics plc authorized a Form 25 filing to voluntarily delist its American Depositary Shares from The Nasdaq Capital Market.8-K
- The Company intends to file the Form 25 on or about October 28, 2025.8-K
- Trading of the Company’s ADSs on Nasdaq is expected to be suspended around October 27, 2025.8-K
- Deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to be effective ninety days after the filing of the Form 25.8-K
- Following delisting, the Company plans to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record.8-K
- After delisting, trading of the Company’s ADSs may occur only in privately negotiated sales or on an over-the-counter market.8-K
- The Company issued a press release on October 20, 2025, regarding its voluntary delisting of the ADSs from Nasdaq.8-K
Associated Tickers
Public-market security lifecycles tied to this issuer record.